Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System

NCT ID: NCT00390702

Last Updated: 2018-11-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 103 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2017-05-31

Brief Summary

The Ventricular septal defect (VSD) is the most common of all congenital cardiac malformations. By modifying the Nit-Occlud® PDA Device the Nit-Occlud® Lê VSD Spiral System was designed. as a percutaneous, transcatheter device for occlusion of (peri)membranous and muscular ventricular septum defects (VSD) with a spiral coil. In this clinical investigation feasibility, safety and performance of the new cardiac occluder will be evaluated in accordance with European and US regulations. The study data will be compared to performance criteria for VSD, which are deduced analogue to the published specific Objective Performance Criteria (OPCs) for PDAs. The first part of the study has been performed in three clinical centres in Germany. For the second part in April 2009 four additional clinical centres in Germany, Israel, Italy and Spain were included.

Conditions

Heart Septal Defects, Ventricular

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

VSD occluder

transcatheter implantation of a VSD occluder (Nitinol coil)

Group Type: EXPERIMENTAL

transcatheter implantation of a VSD occluder (Nitinol coil)

Intervention Type: DEVICE

transcatheter implantation, by first performing a arterial-venous loop through the defect

Interventions

transcatheter implantation of a VSD occluder (Nitinol coil)

transcatheter implantation, by first performing a arterial-venous loop through the defect

Intervention Type: DEVICE

Other Intervention Names

Nit-Occlud® Lê VSD Occluder

Eligibility Criteria

Inclusion Criteria

• VSD must be diagnosed by acknowledged methods, like echocardiography
• Signs of left ventricular volume overload are present (left ventricle or left atrium diameters 2 standard deviations greater than normal) and/or measured by catheterisation : Qp/Qs > 1.5
• Pulmonary vascular resistance is less than 4 Wood units
• The patient is older than 24 months
• The VSD has a perimembranous or muscular location.
• A distance between the rim of the VSD and the aortic annulus of at least 3.0 mm (as measured on the 2-D echocardiography - apical 5-chamber view)
• The minimal diameter (size) of the VSD is less than 8.0 mm (as measured on the 2-D echocardiography - apical 5-chamber view)
• Patient must agree to fully participate in the clinical trial and give informed consent in writing. If the patient is without legal ability additionally the person of legal responsibility must agree and s/he must give the informed consent in writing

Exclusion Criteria

Pathological or physical condition precluding the implantation of a Nit-Occlud® Lê VSD coil, such as :

• perimembranous VSD with no evidence of circular aneurysm formation
• Associated cardiac anomalies requiring surgery (greater than mild aortic insufficiency; such as aortic valve prolapse)
• Active endocarditis or other type of sepsis or other active infection at time of implantation
• Thrombus at or near the intended site of implantation
• Thrombus in the vessels through which access to the VSD is gained (unless the patient is protected with an embolic protection device such as a vena cava filter)
• Vessels through which access to the VSD is gained can not accommodate a 7 F sheath
• Potential steric (3-dimensional) interference of the occluder with intracardiac or intravascular structures (like valves)
• History of blood disorder (coagulopathy, tendency towards haemolysis)
• History of hypersensitivity to contrast medium or Nitinol
• AV-block II° or III°, atrial fibrillation, or atrial flutter
• End stage cardiac disease, irreversible major organ failure, or terminal cancer
• HIV infection
• Cerebrovascular disease or neurological deterioration
• Emergency cardiologic intervention
• Patient*) is not able to fully participate in this study including all follow-ups (e.g. for mental or geographical reasons, or patient is intravenous drug user or has strong potential for non-compliance to medical regimes)
• Patient, respectively the person of legal responsibility, is mentally unable to understand the nature, aims, or possible consequences of the clinical investigation
• Pregnant or breast-feeding women
• Patient did participate in another clinical investigation during the last 3 months
• Patient or the person of responsibility has revoked the consent.

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aix Scientifics

INDUSTRY

Sponsor Role: collaborator

pfm medical gmbh

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Meinertz, Prof Dr med

Role: PRINCIPAL_INVESTIGATOR

University Hospital Hamburg Eppendorf, Germany

Locations

Dept. Congem.Heart Defects, Deutsches Herzzentrum

Berlin, , Germany

Cardio-Vascular Centre, Sankt Kathrinen

Frankfurt, , Germany

Univ.Klinikum, Zentrum fuer Kinderheilkunde

Giessen, , Germany

Dept. Paediatric Cardiology, Univ. Hospital Hamburg

Hamburg, , Germany

Dept. Paediatric Cardiology, Univ. Clinic Grosshadern

Munich, , Germany

Meyer Children's Hospital, Rambam Med. Center

Haifa, , Israel

Countries

Germany; Israel

Other Identifiers

pfm 01/2005

Identifier Type: -

Identifier Source: org_study_id